5,173 reports of this reaction
4.1% of all TOPIRAMATE SPINKLE reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for TOPIRAMATE SPINKLE, manufactured by Advagen Pharma Ltd. There are 5,173 FDA adverse event reports linking TOPIRAMATE SPINKLE to OFF LABEL USE. This represents approximately 4.1% of all 124,712 adverse event reports for this drug.
TOPIRAMATE SPINKLE has an overall safety score of 85 out of 100. Patients taking TOPIRAMATE SPINKLE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among TOPIRAMATE SPINKLE users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for TOPIRAMATE SPINKLE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 5,173 FDA reports for TOPIRAMATE SPINKLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 4.1% of all adverse event reports for TOPIRAMATE SPINKLE, making it one of the most commonly reported side effect.
If you experience off label use while taking TOPIRAMATE SPINKLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.